Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
19.37 USD | +3.14% | +2.22% | 0.00% |
May. 16 | ArriVent BioPharma, Inc. Appoints John Hohneker as Board of Directors | CI |
May. 08 | ArriVent BioPharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 629M |
---|---|---|---|---|---|
Net income 2024 * | -78M | Net income 2025 * | -92M | EV / Sales 2024 * | - |
Net cash position 2024 * | 201M | Net cash position 2025 * | 502M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-6.43
x | P/E ratio 2025 * |
-6.34
x | Employees | 40 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.32% |
1 day | +3.14% | ||
1 week | +2.22% | ||
Current month | +16.83% | ||
1 month | +16.83% | ||
3 months | -7.83% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-30 | 19.3 | +2.77% | 12 874 |
24-05-29 | 18.78 | -1.00% | 21,130 |
24-05-28 | 18.97 | -1.40% | 45,529 |
24-05-24 | 19.24 | +1.91% | 81,061 |
24-05-23 | 18.88 | -5.08% | 21,554 |
Delayed Quote Nasdaq, May 30, 2024 at 10:54 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
0.00% | 629M | |
+46.33% | 56.69B | |
-2.99% | 41B | |
+38.25% | 38.11B | |
-11.22% | 26.89B | |
+15.65% | 25.59B | |
-21.91% | 18.59B | |
-0.16% | 12.39B | |
+26.01% | 11.99B | |
+23.11% | 11.88B |
- Stock Market
- Equities
- AVBP Stock